TY - JOUR
T1 - Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite
AU - Grünewald, Thomas G.P.
AU - Bernard, Virginie
AU - Gilardi-Hebenstreit, Pascale
AU - Raynal, Virginie
AU - Surdez, Didier
AU - Aynaud, Marie Ming
AU - Mirabeau, Olivier
AU - Cidre-Aranaz, Florencia
AU - Tirode, Franck
AU - Zaidi, Sakina
AU - Perot, Gaëlle
AU - Jonker, Anneliene H.
AU - Lucchesi, Carlo
AU - Le Deley, Marie Cécile
AU - Oberlin, Odile
AU - Marec-Bérard, Perrine
AU - Véron, Amélie S.
AU - Reynaud, Stephanie
AU - Lapouble, Eve
AU - Boeva, Valentina
AU - Frio, Thomas Rio
AU - Alonso, Javier
AU - Bhatia, Smita
AU - Pierron, Gaëlle
AU - Cancel-Tassin, Geraldine
AU - Cussenot, Olivier
AU - Cox, David G.
AU - Morton, Lindsay M.
AU - MacHiela, Mitchell J.
AU - Chanock, Stephen J.
AU - Charnay, Patrick
AU - Delattre, Olivier
N1 - Funding Information:
T.G.P.G. is supported by a grant from the German Research Foundation (DFG GR3728/2-1), by the Daimler and Benz Foundation in cooperation with the Reinhard Frank Foundation, by LMU Munich’s Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative and by the Mehr LEBEN für krebskranke Kinder–Bettina-Bräu-Stiftung. D.S. is supported by the Institut Curie–SIRIC (Site de Recherche Intégrée en Cancérologie) program. F.C.-A. is supported by a grant from the Asociación Pablo Ugarte and Instituto de Salud Carlos III RTICC RD12/0036/0027. D.G.C. is supported by a grant from the InfoSarcomes Association. The Childhood Cancer Survivor Study is supported by the National Cancer Institute (CA55727, G.T. Armstrong), with funding for genotyping from the Intramural Research Program of the National Institutes of Health, National Cancer Institute. This work was supported by grants from the Institut Curie; INSERM; the Agence Nationale de la Recherche (Investissements d’Avenir) (ANR-10-EQPX-03); the Canceropôle Ile-de-France (ANR10-INBS-09-08); the Ligue Nationale Contre le Cancer (Equipe labellisée); the Institut National du Cancer (PLBIO14-237); the European PROVABES (ERA-649 NET TRANSCAN JTC-2011), ASSET (FP7-HEALTH-2010-259348) and EEC (HEALTH-F2-2013-602856) projects; and the Société Française des Cancers de l’Enfant. The following associations supported this work: Courir pour Mathieu, Dans les pas du Géant, Olivier Chape, Les Bagouzamanon, Enfants et Santé, and les Amis de Claire. The Charnay laboratory was financed by INSERM, the CNRS, the Ministère de la Recherche et Technologie, and the Fondation pour la Recherche Médicale. It has received support under the program “Investissements d’Avenir” launched by the French Government and implemented by the ANR, with the references ANR-10-LABX-54 MEMOLIFE and ANR-11-IDEX-0001-02 PSL* Research University. We thank J. Maris for providing genotype information for the neuroblastoma data set, and we thank L. Liang and W. Cookson for providing access to genotype data on the LCL data set. We thank H. Kovar (Children’s Cancer Research Institute Vienna, Vienna, Austria) for providing cell lines STA-ET-1, STA-ET-3 and STA-ET-8, and F. Redini (University of Nantes, Nantes, France) for providing cell line TC-32. Human MSC lines L87 and V54-2 were kindly provided by P. Nelson (University Hospital LMU, Munich, Germany). We also thank the following clinicians and pathologists for providing samples used in this work: I. Aerts, P. Anract, C. Bergeron, L. Boccon-Gibod, F. Boman, F. Bourdeaut, C. Bouvier, R. Bouvier, L. Brugiéres, E. Cassagnau, J. Champigneulle, C. Cordonnier, J. M. Coindre, N. Corradini, A. Coulomb-Lhermine, A. De Muret, G. De Pinieux, A.S. Defachelles, A. Deville, F. Dijoud, F. Doz, C. Dufour, K. Fernandez, N. Gaspard, L. Galmiche-Rolland, C. Glorion, A. Gomez-Brouchet, J.M. Guinebretiere, H. Jouan, C. Jeanne-Pasquier, B. Kantelip, F. Labrousse, V. Laithier, F. Larousserie, G. Leverger, C. Linassier, P. Mary, G. Margueritte, E. Mascard, A. Moreau, J. Michon, C. Michot, F. Millot, Y. Musizzano, M. Munzer, B. Narciso, O. Oberlin, D. Orbach, H. Pacquement, Y. Perel, B. Petit, M. Peuchmaur, J.Y. Pierga, C. Piguet, S. Piperno-Neumann, E. Plouvier, D. Ranchere-Vince, J. Rivel, C. Rouleau, H. Rubie, H. Sartelet, G. Schleiermacher, C. Schmitt, N. Sirvent, D. Sommelet, P. Terrier, R. Tichit, J. Vannier, J.M. Vignaud and V. Verkarre. We also thank D. Darmon for technical assistance, S. Grossetete-Lalami for bioinformatic assistance, and V.R. Buchholz and E. Butt for critical reading of the manuscript.
Funding Information:
Human samples. Ewing sarcoma patients from France have been referred to the Institut Curie Hospital for molecular diagnosis since 1990. All subjects included in this study had a specific EWSR1-ETS fusion. Constitutional DNA of adequate quality was available for 343 subjects. This study received approval by institutional review boards and ethics committees (Comité de Protection des Personnes Ile-de-France I). Consent was obtained through communication with patients or families either by the referring oncologists or by the Institut Curie Unité de Génétique Somatique. Genomic DNA was isolated from bone marrow or blood via proteinase K lysis and a phenol chloroform extraction method. We included control samples from 251 French subjects originally obtained as part of the Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer project48. All control subjects were male and recruited in the geographical areas close to Paris, Nancy and Brest through participation in a systematic health-screening program funded by the French National Health Insurance. All controls were determined to be unaffected by cancer through medical examination and blood tests for prostate-specific antigen. The sample size was not predetermined.
Publisher Copyright:
© 2015 Nature America, Inc. All rights reserved.
PY - 2015/8/27
Y1 - 2015/8/27
N2 - Deciphering the ways in which somatic mutations and germline susceptibility variants cooperate to promote cancer is challenging. Ewing sarcoma is characterized by fusions between EWSR1 and members of the ETS gene family, usually EWSR1-FLI1, leading to the generation of oncogenic transcription factors that bind DNA at GGAA motifs. A recent genome-wide association study identified susceptibility variants near EGR2. Here we found that EGR2 knockdown inhibited proliferation, clonogenicity and spheroidal growth in vitro and induced regression of Ewing sarcoma xenografts. Targeted germline deep sequencing of the EGR2 locus in affected subjects and controls identified 291 Ewing-associated SNPs. At rs79965208, the A risk allele connected adjacent GGAA repeats by converting an interspaced GGAT motif into a GGAA motif, thereby increasing the number of consecutive GGAA motifs and thus the EWSR1-FLI1-dependent enhancer activity of this sequence, with epigenetic characteristics of an active regulatory element. EWSR1-FLI1 preferentially bound to the A risk allele, which increased global and allele-specific EGR2 expression. Collectively, our findings establish cooperation between a dominant oncogene and a susceptibility variant that regulates a major driver of Ewing sarcomagenesis.
AB - Deciphering the ways in which somatic mutations and germline susceptibility variants cooperate to promote cancer is challenging. Ewing sarcoma is characterized by fusions between EWSR1 and members of the ETS gene family, usually EWSR1-FLI1, leading to the generation of oncogenic transcription factors that bind DNA at GGAA motifs. A recent genome-wide association study identified susceptibility variants near EGR2. Here we found that EGR2 knockdown inhibited proliferation, clonogenicity and spheroidal growth in vitro and induced regression of Ewing sarcoma xenografts. Targeted germline deep sequencing of the EGR2 locus in affected subjects and controls identified 291 Ewing-associated SNPs. At rs79965208, the A risk allele connected adjacent GGAA repeats by converting an interspaced GGAT motif into a GGAA motif, thereby increasing the number of consecutive GGAA motifs and thus the EWSR1-FLI1-dependent enhancer activity of this sequence, with epigenetic characteristics of an active regulatory element. EWSR1-FLI1 preferentially bound to the A risk allele, which increased global and allele-specific EGR2 expression. Collectively, our findings establish cooperation between a dominant oncogene and a susceptibility variant that regulates a major driver of Ewing sarcomagenesis.
UR - http://www.scopus.com/inward/record.url?scp=84940568773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940568773&partnerID=8YFLogxK
U2 - 10.1038/ng.3363
DO - 10.1038/ng.3363
M3 - Article
C2 - 26214589
AN - SCOPUS:84940568773
SN - 1061-4036
VL - 47
SP - 1073
EP - 1078
JO - Nature Genetics
JF - Nature Genetics
IS - 9
ER -